Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
MLN0128
CHF 0.00
In stock
SYN-1157-M0011 mgCHF 135.00
SYN-1157-M0055 mgCHF 227.00
SYN-1157-M01010 mgCHF 369.00
SYN-1157-M05050 mgCHF 1'320.00
SYN-1157-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | MLN-0128; INK-128 |
| Product Type | Chemical |
| Properties | |
| Formula | C15H15N7O |
| MW | 309.3 |
| CAS | 1224844-38-5 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: MEK - MEK5 - MEK2 - MEK1 | Kinase Group: STE | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | GYLDXIAOMVERTK-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
MLN0128 is a potent and selective mTOR inhibitor with an IC(50) of 1nM; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin).
Product References
- Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy: C. García-García, et al.; Clin. Cancer Res. 18, 2603 (2012)
- The translational landscape of mTOR signalling steers cancer initiation and metastasis: A.C. Hsieh, et al.; Nature 485, 55 (2012)
Related Products
